Pharmacogenomics: a key component of personalized therapy

Genome Medicine

Volumn 4, Issue 11, 2012, Pages

  Schwab, Matthias ^a,b   Schaeffeler, Elke ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IVACAFTOR; PANITUMUMAB; TRANSMEMBRANE CONDUCTANCE REGULATOR; VEMURAFENIB; WARFARIN;

BODY MASS; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; DRUG RESPONSE; EDITORIAL; ELECTRONIC MEDICAL RECORD; EPIGENETICS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; METABOLOMICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN PROCESSING; WATER TRANSPORT;

EID: 84870065830     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm394     Document Type: Editorial

References (11)

1. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu Rev Pharmacol Toxicol 2012,
2. Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 2006, 6:162-165. 10.1038/sj.tpj.6500361, 16415920.
3. Eckford PD, Li C, Ramjeesingh M, Bear CE. CFTR potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 2012, 287:36639-36649. 10.1074/jbc.M112.393637, 22942289.
4. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, Miriami E, Karczewski KJ, Hariharan M, Dewey FE, Cheng Y, Clark MJ, Im H, Habegger L, Balasubramanian S, O'Huallachain M, Dudley JT, Hillenmeyer S, Haraksingh R, Sharon D, Euskirchen G, Lacroute P, Bettinger K, Boyle AP, Kasowski M, Grubert F, Seki S, Garcia M, Whirl-Carrillo M, Gallardo M, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293-1307. 10.1016/j.cell.2012.02.009, 22424236.
5. Ward R, . (Ed) Quantitative and Systems Pharmacology in the Post-genomic Era: New Approaches to Discovering Drugs and Understanding Therapeutic Mechanisms. (Ed)., http://www.nigms.nih.gov/nr/rdonlyres/8ecb1f7c-be3b-431f-89e6-a43411811ab1/0/systemspharmawpsorger2011.pdf
6. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2012,
7. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB, . Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:625-629. 10.1038/clpt.2011.185, 3187550,3187550, 21900891, Clinical Pharmacogenetics Implementation Consortium.
8. Schwab M, Schaeffeler E. Warfarin pharmacogenetics meets clinical use. Blood 2011, 18:2938-2939.
9. WarfarinDosing. , http://www.warfarindosing.org
10. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011, 89:379-386. 10.1038/clpt.2010.260, 3204342, 21248726.
11. Mandl KD, Kohane IS. Escaping the EHR trap--the future of health IT. N Engl J Med 2012, 366:2240-2242. 10.1056/NEJMp1203102, 22693995.